Preclinical investigations and a first-in-human phase I trial of M4112 the first dual inhibitor of indoleamine 23-dioxygenase 1 and tryptophan 23-dioxygenase 2 in patients with advanced solid tumors

摘要

M4112 is an oral, potent, and selective indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) dual inhibitor. Here, we report preclinical data and first-in-human phase I data, including safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy, of M4112 monotherapy in patients with advanced solid tumors.